Regional amyloid‐PET clearance dynamics and anti‐Aβ monoclonal antibody therapy: a preliminary real‐world study
Abstract INTRODUCTION Amyloid positron emission tomography (PET) is the reference biomarker for treatment target engagement in anti‐amyloid beta (Aβ) therapies in early symptomatic Alzheimer's disease (AD), yet global metrics may mask a regional heterogeneity of amyloid clearance. METHODS We report real‐world longitudi...